Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Robin Zagala, Nicolas Meyer, Philippe Saiag, Nora Kramkimel, Celeste Lebbe, et al.. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network. Journal of the European Academy of Dermatology and Venereology, In press, ⟨10.1111/jdv.20155⟩. ⟨hal-04626767⟩
-
Alexandra Kachaner, Raphaèle Seror, Fleur Cohen Aubart, Julien Henry, Thierry Lazure, et al.. Complete remission after a single bisphosphonate infusion in isolated bone Langerhans cell histiocytosis lesion: a case report and a narrative review of the literature. JBMR Plus, 2024, 8 (5), pp.ziae043. ⟨10.1093/jbmrpl/ziae043⟩. ⟨hal-04626829⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
Mots clés
Adjuvant
Circulating cell-free DNA
Bisphosphonates
Chemotherapy
Plasma
Assisted reproductive techniques
Cancer bronchique non à petites cellules
BRAF V600E
BRAFV600-mutant melanoma
Immunomodulation
Prognostic
Trametinib
Immunotherapy
Beta-catenin
Prognosis
Wnt
AML
Histiocytosis
Resistance
Anti-CTLA-4
Radiofrequency ablation
Children
Targeted therapy
Adjuvant FOLFOX
Cemiplimab
Biomarkers Colonic neoplasms Machine learning Prognosis Tumour infiltrating lymphocytes
Langerhans cell histiocytosis
EGFR
Anti-PD1
Colorectal carcinoma
Anti-PD-1 antibody
Mesenchymal stromal cells
2-chlorodeoxyadenosine
BRAFV600E mutation
Advanced
Diagnosis
Biomarker
Antibody-drug conjugate
Biliopancreatic diversion
Dabrafenib
Systemic therapy
Gastric bypass
Survival
Sonic Hedgehog
Colon cancer
Acute generalized exanthematous pustulosis
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Body mass index
ACTH
ALK
Crizotinib
Nivolumab
Surgical excision
BRAF
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
Non-small cell lung cancer
Abdominal pain
Antineoplastic agents
Polyomavirus
ALK rearrangement
Androgen insensitivity
Advanced melanoma
Adverse events
Follow-up
Melanoma
Staging
Prevention
ADN tumoral circulant
Abscopal effect colorectal cancer intratumoral immunotherapy liver metastases radiofrequency
Allelic imbalance
Osimertinib
Anti-PD-1
Adjuvant therapy
Anti-Tumor pharmacology
Metastatic
BRAF V600-mutation
Biomarkers
Radiotherapy
BRAFV600E
Circulating tumor DNA
Metastatic cSCC
Bariatric surgery
Colorectal cancer
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Cutaneous squamous cell carcinoma
Chemoresistance
Immunohistochemistry
Immune checkpoint inhibitor
Locally advanced
AZD9291
Abscopal effect
Treatment
Safety
Cancer
Molecular targeted therapies
Invasive cutaneous squamous cell carcinoma
Lung adenocarcinoma
TNM classification
Anti-PD1 blockade
Merkel cell carcinoma